Digistain LTD

Imperial College spin-out and Y-Combinator alumnus Digistain LTD has developed a novel biomarker platform that provides clinicians with an assessment of the likelihood of a patient’s breast cancer recurrence. Designed in collaboration with CRUK by some of the leading names in the field, our solution was created in response to engagement with over 1,500 oncologists worldwide who reported a critical, pressing need for a cheaper and faster method of stratifying patients by risk compared with existing methods.

Utilising infrared spectrometry, the AI-enabled machine learning algorithm analyses patient biopsy samples to generate an accurate risk report predicting the 10-year risk of distant recurrence if treated with 5-year systemic endocrine therapy alone. This report then provides clinicians with the confidence to support their decisions regarding adjuvant chemotherapy, ensuring each patient receives the appropriate treatment tailored to their individual biology.

Unlike traditional methods, the technology is entirely reagent-free and can be deployed in a decentralised manner, utilising existing infrastructure already widely available in routine pathology labs. The result: rapid, scalable risk stratification at a fraction of the cost and turnaround time, helping to reduce delays in treatment initiation and improve access to personalised care.

Our mission is simple: every woman deserves accurate, affordable, and equitable risk stratification, no matter where she lives. We intend to deliver exactly that.